Success Metrics

Clinical Success Rate

100.0%

Based on 1 completed trials

Completion Rate

100%(1/1)

Active Trials

5(83%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

67%

Ph phase_1

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution6 total trials

Phase 1Safety & dosage

2(33.3%)

Phase 2Efficacy & side effects

4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

1 of 1 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(5)

Completed(1)

Detailed Status

Active, not recruiting3

Recruiting2

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (33.3%)

Phase 24 (66.7%)

Trials by Status

active_not_recruiting350%

completed117%

recruiting233%

Recent Activity

5 active trials

Showing 5 of 6

completedphase_2

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

NCT04452955

recruitingphase_2

Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients

NCT07290088

View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT04118114Phase 2

Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors

Completed

NCT07547228Phase 1

A Study of PRL3-zumab in Neovascular Age-related Macular Degeneration (nAMD)

Recruiting

NCT07541001Phase 2

PRL3-Zumab in Patients With Advanced Solid Tumors

Active Not Recruiting

NCT04452955Phase 2

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

Active Not Recruiting

NCT07290088Phase 2

Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor Patients

Recruiting

NCT03191682Phase 1

A First-in-Human Study of PRL3-ZUMAB

Active Not Recruiting

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6